HMC Capital Partners Fund I successfully executing strategy and outperforming

HMC Capital (ASX: HMC) today provided an update on its unlisted fund platform and strategy to establish over $2bn of unlisted funds in the near-term.

HMC also flagged today the strong investment performance of its private equity strategy HMC Capital Partners Fund I (HMCCP).   

HMCCP investee company, Sigma Healthcare (ASX: SIG) recently announced it had been awarded a major supply contract from Chemist Warehouse for a period of five years from 1 July 2024.

Since announcing the contract win, Sigma’s share price is up 35% and has contributed to HMCCP’s strong investment performance. Since inception, the fund has generated a ~16% return for investors, outperforming the S&P/ASX 300 accumulation index by 750bps.

HMC Capital Partners Managing Director, Victoria Hardie, said “We are delighted with the strong investment performance to date which is a testament to the fund’s unique investment process and ability to work proactively with our investee companies such as Sigma to unlock value. HMCCP is actively deploying into two other high conviction opportunities where we see material upside potential”.

Watch Victoria's most recent interview on HMCCP below.